Stillbirth Risk Identification Using Multiparametric Ultrasound
Launched by UNIVERSITY OF BRITISH COLUMBIA · Apr 8, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to identify the risk of stillbirth by using a special type of ultrasound called quantitative ultrasound from the placenta (QUS-P). The researchers want to find out if this ultrasound can help predict a condition known as perinatal hypoxia, which means the baby isn't getting enough oxygen before birth. The study is currently recruiting pregnant women who are planning to deliver at BC Women's Hospital and are between 19 and 38 years old, with only one baby (singleton) in the womb.
If you decide to participate in this trial, you will undergo ultrasound tests between 35 and 37 weeks of your pregnancy. Your involvement will help researchers learn more about this promising method of risk identification and potentially improve care for future mothers and babies. It's important to know that this study is observational, meaning that while you will receive standard prenatal care, the focus is on gathering information rather than testing a treatment.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Pregnant with singleton
- • 2. Age 19 years or older
- • 3. Provision of informed consent
- • 4. Planning to deliver at BC Women's Hospital
- • 5. 38 weeks gestation or less
- Exclusion Criteria:
- • 1. Pregnant with multiples
- • 2. Not planning to deliver at BC Women's Hospital
- • 3. Less than 19 years of age
- • 4. Greater than 38 weeks gestation
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Robert Rohling, PhD
Principal Investigator
The University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported